Related Experiment Video
Updated: Mar 17, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Pseudoprogression Associated With T-cell Infiltration During Tarlatamab Therapy for Small-Cell Lung Cancer: A Case
Tomoyuki Ikeuchi1, Mitsuhiro Yamamoto1, Hirokazu Toge1
1Department of Respiratory Medicine, National Hospital Organization (NHO) Yonago Medical Center, Yonago, JPN.
Abstract:
Tarlatamab is a bispecific T-cell engager immunotherapy that targets delta-like ligand 3 and CD3. We report a case of pseudoprogression (PsPD) in a patient with small-cell lung cancer treated with tarlatamab. Due to its mechanism, tarlatamab is known to induce T-cell infiltration into tumors. In PsPD, the tumor transiently enlarges because of massive T-cell accumulation within the tumor. In this case, the peripheral blood lymphocyte count decreased, and the interleukin-6 level was markedly elevated, which was thought to reflect T-cell accumulation in the tumor. These trends in the blood tests may be useful in easily differentiating PsPD from true progressive disease during tarlatamab treatment.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10:19Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Immunotherapy